Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En fase 2/3-studie for å evaluere sikkerheten og effekten av EIK1001-006 i kombinasjon med Pembrolizumab versus placebo og Pembrolizumab som førstelinjebehandling hos pasienter med avansert melanom

2. oktober 2026 oppdatert av: Eikon Therapeutics

En multisenter, randomisert, dobbeltblind, aktiv komparatorkontrollert, adaptiv fase 2/3-studie for å evaluere sikkerheten og effekten av EIK1001 og Pembrolizumab versus placebo og Pembrolizumab som førstelinjebehandling hos deltakere med avansert melanom.

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

This is a Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma. The study includes dose optimization and expansion parts.

Studietype

Intervensjonell

Registrering (Antatt)

740

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Krishna Kaza, Director Clinical Study Management
  • Telefonnummer: +1 (516) 675-6163
  • E-post: Kazak@eikontx.com

Studiesteder

    • New South Wales
    • Queensland
      • Chermside, Queensland, Australia, 4032
        • Rekruttering
        • Icon Cancer Centre Chermside
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Chun Gan
    • South Australia
      • Bedford Park, South Australia, Australia, 5042
        • Rekruttering
        • Southern Adelaide Local Health Network Incorporated Flinders Medical Centre
        • Hovedetterforsker:
          • Amitesh Roy
        • Ta kontakt med:
        • Ta kontakt med:
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Rekruttering
        • Eastern Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Phillip Parente
        • Underetterforsker:
          • Zhen R Siow
      • Frankston, Victoria, Australia, 3199
        • Rekruttering
        • Peninsula and South Eastern Haematology and Oncology Group
        • Hovedetterforsker:
          • Vinod Ganju
        • Ta kontakt med:
      • Sint-Niklaas, Belgia, 9100
        • Rekruttering
        • Vitaz Primary Location
        • Hovedetterforsker:
          • Ines Deleu
        • Ta kontakt med:
    • Antwerpen
      • Edegem, Antwerpen, Belgia, 2650
        • Rekruttering
        • Universitair Ziekenhuis Antwerpen
        • Hovedetterforsker:
          • Marika Rasschaert
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Timon Vandamme
    • Brussels Capital
      • Brussels, Brussels Capital, Belgia, 1200
    • Namur
      • Yvoir, Namur, Belgia, B-5530
        • Rekruttering
        • Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Laurence Faugeras
        • Underetterforsker:
          • Quentin Gilliaux
    • Vlaams Brabant
      • Leuven, Vlaams Brabant, Belgia, 3000
        • Rekruttering
        • Universitair Ziekenhuis Leuven - Campus Gasthuisberg
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Oliver Bechter
        • Underetterforsker:
          • Patrick Schöffski
    • West-Vlaanderen
      • Kortrijk, West-Vlaanderen, Belgia, 8500
        • Rekruttering
        • Algemeen Ziekenhuis Groeninge - Campus Kennedylaan
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Veronique Buyse
        • Underetterforsker:
          • Tine Loyson
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Rekruttering
        • Sunnybrook Research Ins<tute
        • Hovedetterforsker:
          • Rossanna Pezo
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Teresa Petrella
    • Central Jutland
      • Aarhus, Central Jutland, Danmark, 8200
        • Suspendert
        • Aarhus Universitetshospital
    • Nord Jutland
      • Aalborg, Nord Jutland, Danmark, 9000
        • Suspendert
        • Aalborg University Hospital
    • Oulu
      • Oulu, Oulu, Finland, 90230
        • Rekruttering
        • Oulu University Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sanna Livanainen
    • Pirkanmaa
      • Tampere, Pirkanmaa, Finland, 33521
        • Rekruttering
        • Tampere University Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tanja Skyttä
    • Uusimaa
      • Helsinki, Uusimaa, Finland, 00029
        • Rekruttering
        • Helsinki University Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Micaela Hernberg
    • Arizona
      • Chandler, Arizona, Forente stater, 85224
        • Rekruttering
        • Ironwood Cancer & Research Centers
        • Ta kontakt med:
        • Hovedetterforsker:
          • Amikar Sehdev, MD
    • Arkansas
      • Hot Springs, Arkansas, Forente stater, 71913
        • Rekruttering
        • Genesis Cancer and Blood Institute
        • Hovedetterforsker:
          • Robert Muldoon
        • Ta kontakt med:
    • California
      • Los Angeles, California, Forente stater, 90015
      • Santa Rosa, California, Forente stater, 95403
        • Rekruttering
        • Providence Medical Foundation
        • Hovedetterforsker:
          • David Park
        • Underetterforsker:
          • Natalie Valle
        • Ta kontakt med:
    • Colorado
      • Colorado Springs, Colorado, Forente stater, 80909
        • Rekruttering
        • UCHealth Memorial Hospital Central
        • Ta kontakt med:
        • Hovedetterforsker:
          • Stacey ParkerBrueggemann, MD
    • Delaware
      • Newark, Delaware, Forente stater, 19713
    • Florida
      • Hialeah, Florida, Forente stater, 33013
      • Tamarac, Florida, Forente stater, 33321
        • Rekruttering
        • Florida Clinical Trials Group - Tamarac
        • Hovedetterforsker:
          • Chintan Gandhi
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Lauren Brito
    • Maryland
      • Bethesda, Maryland, Forente stater, 20817
        • Rekruttering
        • The Center for Cancer and Blood Disorders
        • Hovedetterforsker:
          • Victor Priego
        • Ta kontakt med:
    • Missouri
      • Kansas City, Missouri, Forente stater, 64132
        • Rekruttering
        • MidAmerica Cancer Care
        • Hovedetterforsker:
          • Jaswinder Singh
        • Ta kontakt med:
      • St Louis, Missouri, Forente stater, 63108
        • Rekruttering
        • Washington University School of Medicine in St. Louis
        • Hovedetterforsker:
          • George Ansstas
        • Ta kontakt med:
        • Underetterforsker:
          • Nicole Chrisman
    • Ohio
      • Canton, Ohio, Forente stater, 44718
        • Rekruttering
        • Gabrail Cancer Center Research LLC
        • Hovedetterforsker:
          • Nashat Gabrail
        • Ta kontakt med:
        • Underetterforsker:
          • Carmen Baldwin
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • Rekruttering
        • University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center
        • Hovedetterforsker:
          • Diwakar Davar, MD
        • Ta kontakt med:
    • Texas
      • Sugar Land, Texas, Forente stater, 77479
        • Rekruttering
        • Patientcare Clinical Research
        • Hovedetterforsker:
          • Amir Rasheed
        • Ta kontakt med:
        • Underetterforsker:
          • Jianwen Dong
      • Bordeaux, Frankrike, 33075
        • Rekruttering
        • Hospital Saint Andre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Caroline Dutriaux
    • Auvergne-Rhône-Alpes
      • Pierre-Bénite, Auvergne-Rhône-Alpes, Frankrike, 69495
        • Rekruttering
        • Centre Hospitalier Lyon-Sud
        • Hovedetterforsker:
          • Stéphane Dalle
        • Ta kontakt med:
    • Boulogne
      • Boulogne, Boulogne, Frankrike, 92104
    • Isère
      • La Tronche, Isère, Frankrike, 38700
        • Rekruttering
        • Centre Hospitalier Universitaire Grenoble Alpes
        • Hovedetterforsker:
          • Julie Charles
        • Ta kontakt med:
    • Lille Cedex
      • Lille, Lille Cedex, Frankrike, 59037
    • Marseille
      • Marseille, Marseille, Frankrike, 13385
        • Rekruttering
        • Hôpital La Timone
        • Ta kontakt med:
        • Hovedetterforsker:
          • Caroline Gaudy
    • PACA
      • Nice, PACA, Frankrike, 06200
        • Rekruttering
        • Centre Hospitalier Universitaire (CHU) Nice
        • Ta kontakt med:
        • Hovedetterforsker:
          • Henri Montaudie
    • Paris
      • Paris, Paris, Frankrike, 75018
        • Rekruttering
        • Hôpital Bichat AP-HP Université Paris Cité
        • Ta kontakt med:
        • Hovedetterforsker:
          • Florence Brunet-Possenti
    • Pays de la Loire Region
      • Saint-Herblain, Pays de la Loire Region, Frankrike, 44800
    • Rouen
      • Rouen, Rouen, Frankrike, 76031
        • Rekruttering
        • CHU Rouen
        • Ta kontakt med:
        • Hovedetterforsker:
          • Anne Benedicte Duval Modeste
    • Be'er Sheva
      • Beersheba, Be'er Sheva, Israel, 8410101
        • Rekruttering
        • Soroka medical center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander Yakobson
    • Petach Tikva
      • Petah Tikva, Petach Tikva, Israel, 4941492
        • Rekruttering
        • Rabin Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nethanel Asher
    • Ramat Gan
      • Ramat Gan, Ramat Gan, Israel, 5262100
        • Rekruttering
        • Ella Lemelbaum Institute for Immuno-Oncology and Melanoma
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ronnie Shapira-Frommer
        • Underetterforsker:
          • Raz Mutai
    • Tel Aviv
      • Tel Aviv, Tel Aviv, Israel, 6423906
        • Rekruttering
        • Tel Aviv Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mor Miodovnik
    • Foggia
      • San Giovanni Rotondo, Foggia, Italia, 71013
        • Rekruttering
        • Ospedale Casa Sollievo Della Sofferenza
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gabriele Di Maggio
        • Underetterforsker:
          • Antonella Centonza
    • Italy
      • Alessandria, Italy, Italia, 15121
        • Rekruttering
        • Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare Arrigo
        • Hovedetterforsker:
          • Federica Grosso
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Delfanti Sara
      • Messina, Italy, Italia, 98039
        • Rekruttering
        • Ospedale San Vincenzo Taormina
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Francesco Ferraù
        • Underetterforsker:
          • Elena Torrisi
      • Milan, Italy, Italia, 20133
      • Modena, Italy, Italia, 41125
        • Rekruttering
        • AOU Policlinico di Modena
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Roberta Depenni
        • Underetterforsker:
          • Stefano Greco
      • Padova, Italy, Italia, 35128
        • Rekruttering
        • Istituto Oncologico Veneto IRCCS
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jacopo Pigozzo
        • Underetterforsker:
          • Luisa Piccin
      • Trento, Italy, Italia, 38123
        • Rekruttering
        • Azienda Provinciale per I Servizi Sanitari
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sonia Brugnara
        • Underetterforsker:
          • Federico Sganzerla
    • Liguria
      • Genoa, Liguria, Italia, 16132
        • Rekruttering
        • IRCCS Ospedale Policlinico San Marino
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Francesco Spagnolo
        • Underetterforsker:
          • Andrea Boutros
    • Milano
      • Milan, Milano, Italia, 20132
        • Rekruttering
        • IRCCS Ospedale San Raffaele
        • Ta kontakt med:
        • Hovedetterforsker:
          • Vincenzo Russo
    • Province of Bergamo
      • Bergamo, Province of Bergamo, Italia, 24125
        • Rekruttering
        • Humanitas Gavazzeni Bergamo
        • Ta kontakt med:
        • Hovedetterforsker:
          • Laura Pala
    • The Marches
      • Ancona, The Marches, Italia, 60126
    • Tuscany
      • Siena, Tuscany, Italia, 53100
        • Rekruttering
        • UOC Immunoterapia Oncologica
        • Ta kontakt med:
        • Hovedetterforsker:
          • Anna Maria Di Giacomo
    • Christchurch
      • Christchurch, Christchurch, New Zealand, 8011
        • Rekruttering
        • Christchurch Public Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • David Gibbs
    • New Zealand
      • Auckland, New Zealand, New Zealand, 1023
        • Rekruttering
        • Auckland City Hospital
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gareth Rivalland, MD
    • Bodø
      • Bodø, Bodø, Norge, N-8005
        • Rekruttering
        • Nordland Hospital Trust
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bard Mannsaker
    • Oslo
      • Oslo, Oslo, Norge, 0310
        • Rekruttering
        • Oslo University Hospital - The Norwegian Radium Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Marta Nyakas
    • Oslofjord
      • Drammen, Oslofjord, Norge, 3004
        • Rekruttering
        • Drammen Hospital
        • Ta kontakt med:
        • Underetterforsker:
          • Alina Carmen Porojnicu
    • Gdańsk
      • Gdansk, Gdańsk, Polen, 80-952
        • Rekruttering
        • Uniwersyteckie Centrum Kliniczne
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kamil Drucis
    • Konin
      • Konin, Konin, Polen, 62-500
        • Rekruttering
        • Prezychodnia Lekarska KOMED Roman Karaszewski
        • Hovedetterforsker:
          • Bogusława Karaszewska
        • Ta kontakt med:
    • Siedlce
      • Siedlce, Siedlce, Polen, 08-110
        • Rekruttering
        • Mazowiecki Szpital Wojewódzki, Siedlckie Centrum Onkologii
        • Hovedetterforsker:
          • Lubomir Bodnar
        • Ta kontakt med:
    • Silesian Voivodeship
      • Gliwice, Silesian Voivodeship, Polen, 44-102
        • Rekruttering
        • Maria Sklodowska-Curie Na;onal Research Ins;tute of Oncology, Gliwice Branch
        • Hovedetterforsker:
          • Wieslaw Bal
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Anna Kotas
    • Warsaw
      • Warsaw, Warsaw, Polen, 02-781
        • Rekruttering
        • Maria Sklodowska-Curie National Cancer Research Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Anna Czarnecka
    • Lisbon District
      • Lisbon, Lisbon District, Portugal, 1500-650
        • Rekruttering
        • Hospital da Luz Lisboa
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gonçalo Fernandes
      • Lisbon, Lisbon District, Portugal, 1099-023
        • Rekruttering
        • IPO Lisboa
        • Ta kontakt med:
        • Hovedetterforsker:
          • Patricia Pereira
    • Belgrade
      • Belgrade, Belgrade, Serbia, 11000
        • Rekruttering
        • Military Medical Academy- Department of Oncology
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lidija Kandolf
      • Cadiz, Spania, 11407
        • Rekruttering
        • University Hospital of Jerez
        • Ta kontakt med:
        • Hovedetterforsker:
          • Regina Garcia Galindo
        • Underetterforsker:
          • Gloria Aguilera
    • A Coruña
      • Santiago de Compostela, A Coruña, Spania, 15706
        • Rekruttering
        • Hospital Clínico de Santiago de Compostela
        • Ta kontakt med:
        • Hovedetterforsker:
          • Teresa Curiel
        • Underetterforsker:
          • Alexandra Mosquera
    • Badalona
      • Badalona, Badalona, Spania, 08916
        • Rekruttering
        • H. Germans Trias I Pujol (ICO-Badalona)
        • Ta kontakt med:
        • Hovedetterforsker:
          • José Manzano
    • Barcelona
      • Barcelona, Barcelona, Spania, 08028
        • Rekruttering
        • Hospital Universitari Dexeus
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Maria G Cao
        • Underetterforsker:
          • Josep S Ortega
      • Barcelona, Barcelona, Spania, 08035
        • Rekruttering
        • Vall d' Hebron Institute of Oncology
        • Ta kontakt med:
          • Alba Barrio
          • Telefonnummer: 8827 (+34) 93 254 34 50
          • E-post: bbruno@vhio.net
        • Ta kontakt med:
          • Núria Llansana
          • Telefonnummer: 5063 (+34) 93 254 3450
          • E-post: nfarras@vhio.net
        • Hovedetterforsker:
          • Eva M Couselo
    • Cantabria
      • Santander, Cantabria, Spania, 39008
        • Rekruttering
        • Hospital Universitario Marques de Valdecilla
        • Hovedetterforsker:
          • Marta García
        • Ta kontakt med:
        • Underetterforsker:
          • Belen Caramelo
    • Cáceres
      • Cáceres, Cáceres, Spania, 10003
    • Galicia
      • Lugo, Galicia, Spania, 27003
        • Rekruttering
        • Hospital Universitario Lucus Augusti
        • Ta kontakt med:
        • Hovedetterforsker:
          • Begona Campos Balea
    • Girona
      • Girona, Girona, Spania, 17007
        • Rekruttering
        • Institut Català d'Oncologia Girona (ICO Girona)
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Anna Carbó
        • Hovedetterforsker:
          • Elisabet Bujons
    • Madrid
      • Madrid, Madrid, Spania, 28007
        • Rekruttering
        • Hospital General Universitario Gregorio Marañón
        • Ta kontakt med:
        • Hovedetterforsker:
          • IVAN MARQUEZ
      • Madrid, Madrid, Spania, 28002
        • Rekruttering
        • GenesisCare Madrid - Hospital San Francisco de Asís
        • Ta kontakt med:
        • Hovedetterforsker:
          • José Angel Garcia Cuesta
      • Madrid, Madrid, Spania, 28050
        • Rekruttering
        • HM CIOCC
        • Ta kontakt med:
        • Hovedetterforsker:
          • Juan Rodriguez Moreno
      • Usera, Madrid, Spania, 28031
        • Rekruttering
        • Hospital 12 de Octubre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Guillermo De Velasco
    • Malaga
      • Málaga, Malaga, Spania, 29011
        • Rekruttering
        • Hospital Regional Universitario
        • Ta kontakt med:
        • Hovedetterforsker:
          • Miguel Angel Berciano
    • Murcia
      • Murcia, Murcia, Spania, 30120
        • Rekruttering
        • Hospital Clinico Universitario Virgen de la Arrixaca
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pablo Fuentes
        • Underetterforsker:
          • Miguel Angel Moya
    • Málaga
      • Málaga, Málaga, Spania, 29010
        • Rekruttering
        • Hospital Universitario Virgen de la Victoria
        • Ta kontakt med:
        • Hovedetterforsker:
          • Manuel Zalabardo
    • Spain
      • Barcelona, Spain, Spania, 8036
        • Rekruttering
        • Hospital Clinic Barcelona
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ana Arance
        • Underetterforsker:
          • Maribel Marmol
    • Valencia
      • Valencia, Valencia, Spania, 46009
        • Rekruttering
        • IVO - Fundacion Instituto Valenciano de Oncologia
        • Hovedetterforsker:
          • Maria Jose Juan Fita
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Eduardo Nagore
      • Valencia, Valencia, Spania, 46010
        • Rekruttering
        • INCLIVA Instituto de Investigación Sanitaria
        • Underetterforsker:
          • Valentina Gambardella
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ines G Barrallo
    • Belfast
      • Belfast, Belfast, Storbritannia, BT9 7AB
        • Rekruttering
        • Belfast City Hospital, Belfast Health and Social Care Trust
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bode Oladipo
    • England
      • London, England, Storbritannia, SE1 9RT
        • Rekruttering
        • Guy's and St Thomas' NHS Foundation Trust
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alvin Lee
      • London, England, Storbritannia, W1G6AD
        • Rekruttering
        • Sarah Cannon Research Institute London
        • Hovedetterforsker:
          • Anja Williams
        • Ta kontakt med:
        • Underetterforsker:
          • Elisa Fontana
    • Hampshire
      • Southampton, Hampshire, Storbritannia, SO32 2DA
        • Rekruttering
        • University Hospital Southampton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Matthew Wheater
    • Canton of Zurich
      • Zurich, Canton of Zurich, Sveits, 8091
        • Rekruttering
        • Universitätsspital Zürich
        • Hovedetterforsker:
          • Egle Ramelyte
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Michele Welti
    • Chur
      • Chur, Chur, Sveits, 7000
        • Rekruttering
        • Kantonsspital Graubünden
        • Ta kontakt med:
        • Hovedetterforsker:
          • Roger von Moos
    • Gävleborg County
      • Gävle, Gävleborg County, Sverige, 801 88
        • Rekruttering
        • Gävle Sjukhus
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ilke Cikman
        • Underetterforsker:
          • Olga Del Val Munoz
    • Södermanland County
      • Stockholm, Södermanland County, Sverige, 17176
      • Daegu, Sør -Korea, 41404
        • Rekruttering
        • Kyungpook National University Chilgok Hospital
        • Hovedetterforsker:
          • Soo Jung Lee
        • Ta kontakt med:
        • Underetterforsker:
          • In Hee Lee
      • Seoul, Sør -Korea, 03080
        • Rekruttering
        • Seoul National University Hospital
        • Hovedetterforsker:
          • Miso Kim
        • Ta kontakt med:
        • Underetterforsker:
          • Seo Yoon Jang
    • Eastern Cape
      • Port Elizabeth, Eastern Cape, Sør-Afrika, 6045
        • Rekruttering
        • Cancercare Port Elizabeth - Langenhoven Drive Oncology Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • John Crockett
        • Underetterforsker:
          • Sakina Bawa
    • Gauteng
      • Pretoria, Gauteng, Sør-Afrika, 0002
        • Rekruttering
        • University of Pretoria, Steve Biko Academic Hospital
        • Hovedetterforsker:
          • Richard Khanyile
        • Ta kontakt med:
      • Saxonwold, Gauteng, Sør-Afrika, 2196
        • Rekruttering
        • The Medical Oncology Centre of Rosebank
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bernardo Rapoport
    • KwaZulu-Natal
      • Richards Bay, KwaZulu-Natal, Sør-Afrika, 3900
        • Rekruttering
        • Abraham Oncology
        • Hovedetterforsker:
          • Smitha Abraham
        • Ta kontakt med:
    • Pretoria
      • Pretoria, Pretoria, Sør-Afrika, 0084
        • Rekruttering
        • Curo Oncology
        • Ta kontakt med:
        • Hovedetterforsker:
          • Rouchelle Marais-Nieman
    • Western Cape
      • Cape Town, Western Cape, Sør-Afrika, 7570
        • Rekruttering
        • Cape Town Oncology Trials
        • Hovedetterforsker:
          • Corlia Coetzee
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Johann Riedemann
      • George, Western Cape, Sør-Afrika, 6529
        • Rekruttering
        • TASK Eden
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Louis Botha
        • Underetterforsker:
          • Alista Easton
    • Brno
      • Brno, Brno, Tsjekkia, 65653
        • Rekruttering
        • Masaryk Memorial Cancer Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Radek Lakomy
        • Underetterforsker:
          • Svatopluk Dobeš
    • Hradce Kralove
      • Sokolov, Hradce Kralove, Tsjekkia, 50009
        • Rekruttering
        • University Hospital Hradec Kralove
        • Hovedetterforsker:
          • Jindrich Kopecky
        • Ta kontakt med:
      • Dresden, Tyskland, 01307
        • Rekruttering
        • University Hospital Carl Gustav Carus Dresden
        • Ta kontakt med:
        • Hovedetterforsker:
          • Friedegund Meier
        • Underetterforsker:
          • Kathlen Hantsch
      • Erfurt, Tyskland, D-99089
      • Gera, Tyskland, 07548
        • Rekruttering
        • SRH Wald-Klinikum Gera GmbH
        • Hovedetterforsker:
          • Sabine Sell
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Anne Meinzenbach
      • Münster, Tyskland, 48157
    • Baden-Wurttemberg
      • Mannheim, Baden-Wurttemberg, Tyskland, 68167
        • Rekruttering
        • Universitätsmedizin Mannheim
        • Hovedetterforsker:
          • Jochen Utikal
        • Ta kontakt med:
      • Tübingen, Baden-Wurttemberg, Tyskland, 72076
        • Rekruttering
        • Universitaetsklinikum Tuebingen (UKT)
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andreas Meiwes
    • Bavaria
      • Würzburg, Bavaria, Tyskland, 97080
        • Rekruttering
        • Klinik für Dermatologie, Venerologie und Allergologie
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Anja Gesierich
    • Erlangen
      • Erlangen, Erlangen, Tyskland, 91054
        • Rekruttering
        • University Hospital Erlangen
        • Ta kontakt med:
        • Hovedetterforsker:
          • Carola Berking
    • Free and Hanseatic City of Hamburg
      • Martinsried, Free and Hanseatic City of Hamburg, Tyskland, 20246
        • Rekruttering
        • Universitätsklinik Hamburg Eppendorf
        • Hovedetterforsker:
          • Christoffer Gebhardt
        • Ta kontakt med:
    • Leipzig
    • Lower Saxony
      • Buxtehude, Lower Saxony, Tyskland, 21614
    • North Rhine-Westphalia
      • Minden, North Rhine-Westphalia, Tyskland, 32429
        • Rekruttering
        • Johannes Wesling Klinikum Minden
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ralf Gutzmer
    • RLP
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Tyskland, 24105
      • Lübeck, Schleswig-Holstein, Tyskland, 23538
        • Rekruttering
        • Universitätsklinikum Schleswig-Holstein - Campus Lübeck
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Evelyn Gaffal
    • State of Berlin
      • Berlin, State of Berlin, Tyskland, 10115
        • Rekruttering
        • Charite Department of Dermatology, Venereology and Allergology
        • Hovedetterforsker:
          • Thomas Eigentler
        • Ta kontakt med:
      • Pécs, Ungarn, 7632
        • Rekruttering
        • University of Pécs
        • Ta kontakt med:
        • Hovedetterforsker:
          • Zsuzsanna Lengyel
    • Budapest
      • Budapest, Budapest, Ungarn, 1122
        • Rekruttering
        • National Institute of Oncology
        • Ta kontakt med:
        • Hovedetterforsker:
          • Timea Balatoni
    • Styria
      • Graz, Styria, Østerrike, 8036
        • Rekruttering
        • Universitätsklinikum Graz
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ingrid Wolf
        • Underetterforsker:
          • Christiane Mutz-Rabl

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

To be eligible for inclusion in this study, participants must:

  • Be ≥ 18 years of age on the day of signing of informed consent.
  • Have a life expectancy of at least 3 months.
  • Have histologically or cytologically confirmed Stage 3 (unresectable) or Stage 4 metastatic melanoma per AJCC 8th ed. and be eligible for standard therapy with pembrolizumab.
  • Have at least 1 lesion with measurable disease at Baseline by CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by assessment of local site Investigator/radiologist.
  • Have known BRAF V600 mutation status or consent to BRAF V600 mutation testing per local institutional standards during the screening period
  • Have completed prior radiotherapy at least 2 weeks prior to study treatment administration.
  • Have an ECOG Performance Status of 0 to 1.
  • Have adequate organ and marrow function as defined by normal CBC, coagulation, serum chemistry and liver function tests on specimens collected within 10 days of treatment start.
  • Have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication (applies to women of childbearing potential [WOCBP]).
  • Be willing to use either 2 adequate methods of contraception, 1 adequate method plus a hormonal method of contraception, or be willing to abstain from heterosexual activity throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to WOCBP who are not menopausal for > 2 years, post-hysterectomy/oophorectomy, or surgically sterilized).
  • Agree to use an approved adequate contraceptive method throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to sexually active male participants with a partner who is WOCBP).
  • Be willing and able to provide written, informed consent for the study.

Exclusion Criteria:

A participant is excluded from the study if any of the following criteria apply:

  • Has melanoma of ocular origin.
  • Is currently enrolled in or has recently participated in a study of an IMP and received an IMP within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001 or placebo.
  • Prior to the 1St dose of EIK1001 or placebo, the prospective participant has received systemic therapy for advanced melanoma.
  • Note: prior adjuvant or neoadjuvant melanoma therapies (such as anti-PD-1 or anti CTLA 4 therapies or BRAF/MEK inhibitors) are permitted if all related AEs have either returned to Baseline or stabilized, with a minimum of 6 months between the last dose of prior therapy and documented disease progression.
  • Experienced a ≥ Grade 3 AE while receiving prior anti PD 1 therapy.
  • Has had major surgery (< 3 weeks prior to the first dose).
  • Has received a live-virus vaccination within 30 days of the first dose of study treatment.
  • Has a known history of prior malignancy, unless the participant has undergone potentially curative therapy with no evidence of disease recurrence for 5 years.
  • Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate if they are clinically stable for at least 4 weeks with no evidence of new or enlarging brain metastases. There must be no need for immunosuppressive doses of glucocorticoids for at least 2 weeks prior to study treatment administration.
  • There is a mean resting QTcF > 470 ms on triplicate electrocardiograms.
  • There is active autoimmune disease that has required systemic treatment in the past 2 years. The following autoimmune conditions are permitted: Type 1 diabetes, hypothyroidism (on hormone replacement), or- vitiligo, psoriasis and alopecia as long as no systemic treatment is required.
  • There is either chronic treatment with systemic steroids, other immunosuppressive medication, or either of these has been administered within 14 days of start of study treatment.
  • Note: Participants with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections are eligible. Steroid replacement for adrenal insufficiency is also permitted.
  • There is a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/ interstitial lung disease.
  • There are any active infections requiring therapy.
  • There is uncontrolled human immunodeficiency virus (HIV) infection. HIV-infected participants with well-controlled HIV may enroll.
  • There is a positive test result for hepatitis B virus (HBV) or HCV indicating presence of virus (it is expected that all participants will have been serologically tested for hepatitis B in advance of this study, with HBsAG, anti-HBc IgG, and anti-HBs as per ASCO 2020 Provisional Clinical Opinion [PCO] on universal Serologic testing for hepatitis B at the onset of anticancer therapy; screening should also include an anti-HCV test prior to start of cancer treatment:
  • There is a history or clinical evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with the participant's participation for the full duration of the study
  • Known psychiatric or substance abuse disorder that would interfere with cooperation with study requirements.
  • There is a known history of regular illicit drug use and/or recent history (within the last year) of substance abuse (including alcohol).
  • Participant is pregnant, breastfeeding, or planning to conceive or father children within the projected duration of the study.
  • Participant is currently receiving medications known to be strong inhibitors or inducers of CYP3A4 and CYP1A2.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Arm 1

Participants in this arm will receive Placebo and Standard of Care (Pembrolizumab).

Pembrolizumab is a PD-1 inhibitor.

Eksperimentell: Arm 2

Participants in this arm will receive EIK1001 (selected dose 1) + Standard of Care (Pembrolizumab).

Pembrolizumab is a PD-1 inhibitor.

EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.

Eksperimentell: Arm 3

Participants in this arm will receive EIK1001 (selected dose 2) + Standard of Care (Pembrolizumab).

Pembrolizumab is a PD-1 inhibitor.

EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression Free Survival (PFS)
Tidsramme: up to 5 years

Progression-free survival (PFS) is defined as the time from the date of randomization to documented progressive disease per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.

up to 5 years
Overall survival (OS)
Tidsramme: up to 5 years

Overall survival (OS) defined as the time from randomization to death due to any cause.

up to 5 years
Objective Response (OR) (Dose Optimization Only)
Tidsramme: up to 5 years

Objective Response (OR; defined as participants who demonstrate confirmed complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator) (Dose Optimization Only).

up to 5 years
Adverse Events (AEs) (Dose Optimization Only)
Tidsramme: up to 2.5 years

Adverse events (AEs), and discontinuation of study treatment due to an AE (Dose Optimization Only). An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

up to 2.5 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Adverse Events (AEs) and Discontinuation of study treatment due to any AE.
Tidsramme: up to 2.5 years

Adverse events (AEs), and discontinuation of study treatment due to any AE. An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

up to 2.5 years
Objective Response (OR)
Tidsramme: up to 5 years

Objective response (OR) is defined as the participants who demonstrate confirmed response (CR) or partial response (PR) according to RECIST 1.1 by BICR.

up to 5 years
Duration of Response (DOR).
Tidsramme: up to 5 years

Duration of Response (DOR) is defined as the time from the first documented evidence of complete response (CR) or partial response (PR) until disease progression or death due to any cause, whichever occurs first according to RECIST 1.1 by BICR.

up to 5 years
Progression Free Survival (PFS)
Tidsramme: up to 5 years

Progression Free Survival (PFS) according to RECIST 1.1 by Investigator.

up to 5 years
Objective Response (OR)
Tidsramme: up to 5 years

Objective Response (OR) according to RECIST 1.1 by Investigator.

up to 5 years
Duration of Response (DOR)
Tidsramme: up to 5 years

Duration of Response (DOR) according to RECIST 1.1 by Investigator

up to 5 years
Duration of Response (DOR) (Dose Optimization Only).
Tidsramme: up to 5 years

Duration of Response (DOR) per RECIST 1.1 by Investigator (Dose Optimization Only).

up to 5 years
Progression-free survival (PFS) per RECIST 1.1 by Investigator (Dose Optimization Only).
Tidsramme: up to 5 years

Progression-free survival (PFS) per RECIST 1.1 by Investigator (Dose Optimization Only).

up to 5 years
Overall survival (OS) (Dose Optimization Only)
Tidsramme: up to 5 years

Overall survival (OS) defined as the time from randomization to death due to any cause (Dose Optimization Only).

up to 5 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studieleder: Etah Kurland, Eikon Therapeutics
  • Studieleder: Muaz Sadeia, Eikon Therapeutics

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. mai 2025

Primær fullføring (Antatt)

1. desember 2035

Studiet fullført (Antatt)

1. desember 2040

Datoer for studieregistrering

Først innsendt

18. november 2024

Først innsendt som oppfylte QC-kriteriene

18. november 2024

Først lagt ut (Faktiske)

20. november 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. oktober 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • EIK1001-006
  • KEYNOTE-G04 (Annen identifikator: Merck Sharp & Dohme LLC)
  • MK-3475-G04 (Annen identifikator: Merck Sharp & Dohme LLC)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere